Literature DB >> 227597

Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.

R T Eagan, S Frytak, E T Creagan, J N Ingle, L K Kvols, D T Coles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 227597

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

1.  The benefit of cisplatin-based polychemotherapy for adenocarcinoma of the lung. The Kyushu Lung Cancer Chemotherapy Study Group.

Authors:  N Hara; M Ohta; Y Ichikawa; T Kanda; K Shima; K Tamura; M Hokama
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 3.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.

Authors:  P Drings; U Abel; H Bülzebruck; P Stiefel; M Kleckow; H G Manke
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group.

Authors:  E C Holmes; L D Hill; M Gail
Journal:  Ann Surg       Date:  1985-09       Impact factor: 12.969

Review 6.  Update in cancer chemotherapy, Part III: Lung cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-10       Impact factor: 1.798
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.